Published in:
01-02-2019 | Correction
Correction to: Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease
Published in: Neurological Sciences | Issue 2/2019
Login to get accessExcerpt
Correction to: Neurological Sciences (2018)
Table 2
Average scores ± SD at baseline (T0) and after the introduction of safinamide (T1), p values of each scale/questionnaire administered
|
Test
|
Average ± SD T0
|
Average ± SD T1
|
P values
|
|---|---|---|---|
|
SCM
|
24.8 ± 9.1
|
14.0 ± 13.0
|
0.001
|
|
NMSS
|
44.3 ± 22.2
|
27.2 ± 25.3
|
0.0003
|
|
MMSE
|
27.2 ± 2.6
|
26.4 ± 4.7
|
0.71
|
|
COG
|
0.3 ± 0.3
|
0.3 ± 0.4
|
0.8
|
|
H&Y
|
2.7 ± 0.5
|
2.8 ± 0.6
|
0.6
|
|
CISI
|
8.0 ± 3.6
|
5.7 ± 3.5
|
0.004
|
|
HADS
|
10.1 ± 7.1
|
5.4 ± 5.3
|
0.132
|
|
PHYS-F
|
39.4 ± 19.8
|
39.4 ± 22.5
|
1
|
|
MENT-F
|
20 ± 17
|
20 ± 14.1
|
1
|
|
PDSS
|
122.4 ± 11.4
|
125.6 ± 11.0
|
0.76
|
|
PDQ8
|
9.4 ± 5.4
|
5.0 ± 5.7
|
0.004
|
|
EQ-5D
|
7.7 ± 2
|
6.5 ± 2.0
|
0.059
|
|
EQ-VAS
|
65 ± 16.2
|
71 ± 19.8
|
0.096
|